Turkkahraman, HakanFlanagan, ShannanZhu, TianliAkel, NisreenMarino, SilviaOrtega-Gonzalez, DayaneYuan, XueBellido, Teresita2024-10-092024-10-092024-07-18Turkkahraman H, Flanagan S, Zhu T, et al. Sclerostin antibody corrects periodontal disease in type 2 diabetic mice. JCI Insight. 2024;9(16):e181940. Published 2024 Jul 18. doi:10.1172/jci.insight.181940https://hdl.handle.net/1805/43857Type 2 diabetes (T2D) is on the rise worldwide and is associated with various complications in the oral cavity. Using an adult-onset diabetes preclinical model, we demonstrated profound periodontal alterations in T2D mice, including inflamed gingiva, disintegrated periodontal ligaments (PDLs), marked alveolar bone loss, and unbalanced bone remodeling due to decreased formation and increased resorption. Notably, we observed elevated levels of the Wnt signaling inhibitor sclerostin in the alveolar bone of T2D mice. Motivated by these findings, we investigated whether a sclerostin-neutralizing antibody (Scl-Ab) could rescue the compromised periodontium in T2D mice. Administering Scl-Ab subcutaneously once a week for 4 weeks, starting 4 weeks after T2D induction, led to substantial increases in bone mass. This effect was attributed to the inhibition of osteoclasts and promotion of osteoblasts in both control and T2D mice, effectively reversing the bone loss caused by T2D. Furthermore, Scl-Ab stimulated PDL cell proliferation, partially restored the PDL fibers, and mitigated inflammation in the periodontium. Our study thus established a T2D-induced periodontitis mouse model characterized by inflammation and tissue degeneration. Scl-Ab emerged as a promising intervention to counteract the detrimental effects of T2D on the periodontium, exhibiting limited side effects on other craniofacial hard tissues.en-USAttribution 4.0 InternationalBone biologyInflammationBone diseaseDiabetesMouse modelsArticle